That se­cre­tive ARCH biotech with two an­ti­bod­ies from Mor­phoSys? It’s now got $120M

In June, HI-Bio, short for Hu­man Im­munol­o­gy Bio­sciences, li­censed two can­di­dates from Ger­man biotech Mor­phoSys — felzartam­ab for two au­toan­ti­body kid­ney dis­eases, and HIB210, which goes af­ter the C5a re­cep­tor, the same tar­get that new Am­gen sub­sidiary Chemo­Cen­tryx’s drug won ap­proval on last year. HI-Bio holds the rights on the two can­di­dates every­where ex­cept Greater Chi­na, as well as Ko­rea for HIB210, where the rights be­long to I-Mab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER